<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Milrinone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Milrinone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Milrinone: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11988" href="/d/html/11988.html" rel="external">see "Milrinone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12613" href="/d/html/12613.html" rel="external">see "Milrinone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F196770"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Inotrope;</li>
<li>
                        Phosphodiesterase-3 Enzyme Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F196741"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="544fdb8d-9360-4b5b-be1d-3c8dd40a45be">Acute decompensated heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute decompensated heart failure:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May consider for short-term use in patients with low cardiac index and hypotension or end-organ hypoperfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: <b>IV:</b> Initial: 0.125 to 0.25 mcg/kg/minute; titrate based on clinical end point (eg, systemic perfusion or end organ perfusion); usual dosage range: 0.125 to 0.75 mcg/kg/minute. <b>Note:</b> IV bolus loading doses are not recommended due to risk of hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96392096-f13d-4bf4-b195-484794ca07eb">Postoperative inotropic support, heart transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative inotropic support, heart transplant recipients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: <b>IV:</b> Usual dose range: 0.375 to 0.75 mcg/kg/minute; titrate to the lowest effective dose based on clinical response and hemodynamic end points; wean as tolerated over the first 3 to 5 days following surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37080658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37080658'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990668"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Conservative initial doses should be utilized, as clearance is highly dependent on kidney function. Titrate dose based on clinical end points. Monitor closely for adverse effects, such as arrhythmias and hypotension, which may occur more frequently with kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-23620310','lexi-content-ref-29045285','lexi-content-ref-23695773','lexi-content-ref-18477069','lexi-content-ref-21976129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-23620310','lexi-content-ref-29045285','lexi-content-ref-23695773','lexi-content-ref-18477069','lexi-content-ref-21976129'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 10 to 50 mL/minute: Initial: 0.0625 to 0.125 mcg/kg/minute depending on indication and degree of kidney impairment; titrate cautiously, especially with worsening kidney function. Titrating to &gt;0.375 mcg/kg/minute in significant kidney impairment is generally not recommended due to likelihood for accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rodgers.2016','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rodgers.2016','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;10 mL/minute: Not established; consider alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29045285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29045285'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987909"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doo drugH1Div" id="F56796965"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, or 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion: IV:</b> Use <b>ideal body weight</b> for initial weight-based dosing, then titrate to hemodynamic effect and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). During therapy, clinicians should <b>not</b> change dosing weight from one weight metric to another (ie, actual body weight to/from ideal body weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33622380','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33622380','lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b> There is a paucity of studies evaluating the influence of obesity on milrinone dosing or pharmacokinetics. Milrinone has a small V<sub>d</sub>; clearance is affected by kidney dysfunction and milrinone is typically titrated to clinical end points (eg, end organ perfusion, cardiac output/index). Adverse effects may be more frequent with higher doses and/or kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F196742"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F46886656"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12613" href="/d/html/12613.html" rel="external">see "Milrinone: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing should be individualized and titrated to effect due to interpatient variability in clearance, with or without low cardiac output syndrome or acute kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15346851','lexi-content-ref-23435950','lexi-content-ref-25860636','lexi-content-ref-23839530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15346851','lexi-content-ref-23435950','lexi-content-ref-25860636','lexi-content-ref-23839530'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0aaecd9a-fa24-4a15-9c5b-a253afdc5ee0">Hemodynamic support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodynamic support (eg, acute decompensated heart failure, cardiogenic shock, fluid-refractory, catecholamine-resistant septic shock):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose (optional): IV, Intraosseous: 50 mcg/kg administered over 10 to 60 minutes followed by a continuous IV or intraosseous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kleinman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kleinman.1'])">Ref</a></span>). <b>Note: </b>Due to the risk of hypotension, some centers do not utilize a loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV or intraosseous infusion: Dose range: 0.25 to 0.75 mcg/kg/minute; titrate dose to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kleinman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kleinman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf1f623e-2c67-40aa-8e93-aaffedc48638">Low cardiac output syndrome following congenital heart disease corrective surgery, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Low cardiac output syndrome (LCOS) following congenital heart disease (CHD) corrective surgery, prevention:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: IV: Loading dose: 75 mcg/kg administered over 60 minutes followed by a continuous IV infusion of 0.75 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12600913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12600913'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159453"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. Milrinone clearance is significantly reduced and other pharmacokinetic parameters (eg, volume of distribution) have shown a high degree of interpatient variability in pediatric patients with acute kidney injury; doses should be individualized and titration based upon hemodynamic and clinical response rather than an algorithmic approach based upon dose adjustment for estimated creatinine clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25860636','lexi-content-ref-23839530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25860636','lexi-content-ref-23839530'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51159454"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F196713"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Ventricular arrhythmia (nonsustained ventricular tachycardia [3%], ventricular ectopy [9%], ventricular fibrillation [&lt;1%], ventricular tachycardia [1%])</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (≤1%), chest pain (≤1%), hypotension (3%), supraventricular cardiac arrhythmia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (Kaakeh 2012), tachycardia, (Alhashemi 1998), torsades de pointes</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm</p></div>
<div class="block coi drugH1Div" id="F196726"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to milrinone or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F196710"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Ventricular arrhythmias, including nonsustained ventricular tachycardia and supraventricular arrhythmias, have been reported. Observe closely for arrhythmias in this very high-risk patient population; sudden cardiac death has been observed. Due to the prolonged half-life as compared to other inotropic agents, ventricular or atrial arrhythmias may persist even after discontinuation of milrinone especially in patients with kidney dysfunction (Cox 2013; Leier 1998). Ensure that ventricular rate is controlled in atrial fibrillation/flutter before initiating; may increase ventricular response rate. In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death (Brozena 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Hypotension may occur. Monitor blood pressure closely. Hypotension may be prolonged especially in patients with kidney dysfunction (Cox 2013; Leier 1998). Vigorous diuresis may contribute to hypotension; cautious administration of fluids may be required to prevent hypotension. Omitting the bolus dose may decrease the risk of hypotension (Baruch 2001; Cuffe 2002). If hypotension occurs, consider dose reduction or temporary discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Avoid use in patients with severe obstructive aortic or pulmonic valvular disease in lieu of surgical relief of the obstruction; may aggravate outflow tract obstruction in hypertrophic cardiomyopathy with outflow tract obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; reduction in infusion rate recommended. Hypotension may be prolonged in patients with kidney dysfunction (Cox 2013; Leier 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: A facility for immediate treatment of potential cardiac events, including life-threatening ventricular arrhythmias, must be available. Safe and effective use beyond 48 hours (prolonged use) has not been demonstrated. An increased risk of death and hospitalization has been observed with prolonged use in NYHA Class III/IV heart failure patients. Sudden cardiac death has been reported with prolonged use. Continuous electrocardiographic monitoring is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Long-term therapy: According to heart failure guidelines, long-term use of IV inotropic therapy without a specific indication or for reasons other than palliation is potentially harmful (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block foc drugH1Div" id="F196720"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as lactate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mcg/mL (100 mL, 200 mL); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL); 50 mg/50 mL (50 mL); 20 mg/100 mL in Dextrose 5% (100 mL); 40 mg/200 mL with Dextrose 5% (200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as lactate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mcg/mL (100 mL [DSC], 200 mL [DSC]); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL); 50 mg/50 mL (50 mL); 20 mg/100 mL in Dextrose 5% (100 mL); 40 mg/200 mL with Dextrose 5% (200 mL)</p></div>
<div class="block geq drugH1Div" id="F196706"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323415"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Milrinone Lactate in Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/100 mL 5% (per mL): $0.18 - $0.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/200 mL 5% (per mL): $0.18 - $0.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Milrinone Lactate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/10 mL (per mL): $0.47 - $0.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/20 mL (per mL): $0.33 - $1.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/50 mL (per mL): $0.41 - $0.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867569"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as lactate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (10 mL, 20 mL)</p></div>
<div class="block adm drugH1Div" id="F196723"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV use only. Administer loading dose (optional) undiluted slowly over 10 minutes; diluting to a rounded total volume of 10 or 20 mL may simplify the visualization of the injection rate. Infuse maintenance dose via continuous infusion pump.</p></div>
<div class="block admp drugH1Div" id="F52613339"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV, Intraosseous:</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: Administer undiluted or diluted by slow IV push over at least 10 minutes; to minimize hypotension, slower infusion rates up to 60 minutes may also be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7587268','lexi-content-ref-12600913','lexi-content-ref-23132395','lexi-content-ref-Kleinman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7587268','lexi-content-ref-12600913','lexi-content-ref-23132395','lexi-content-ref-Kleinman.1'])">Ref</a></span>) or the loading dose may be divided into five equal doses and each dose is administered over 10 minutes if blood pressure remains within an acceptable range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV or Intraosseous infusion: Administer as a continuous IV infusion with the use of an infusion pump or syringe pump or an intraosseous infusion until IV access can be obtained in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kleinman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kleinman.1'])">Ref</a></span>). Avoid extravasation; administration into a large vein may help prevent the possibility of extravasation; some suggest central-line administration is preferred, especially in neonates; administration into an umbilical arterial catheter is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p></div>
<div class="block uica drugH1Div" id="F14472935"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 20 mg in 100 mL (total volume) (concentration: 200 <b>mcg</b>/mL) of D<sub>5</sub>W  </p></div>
<div class="block uicp drugH1Div" id="F14472936"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 100 <b>mcg</b>/mL, 200 <b>mcg</b>/mL.</p></div>
<div class="block use drugH1Div" id="F196721"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute decompensated heart failure:</b> Short-term IV therapy for patients with acute decompensated heart failure with reduced ejection fraction in need of inotropic support.</p></div>
<div class="block off-label drugH1Div" id="F25730538"><span class="drugH1">Use: Off-Label: Adult</span><p>Postoperative inotropic support, heart transplant recipients</p></div>
<div class="block mst drugH1Div" id="F196778"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Primacor may be confused with Primaxin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299715"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221703"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the adverse/toxic effect of Milrinone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Milrinone may enhance the hypotensive effect of Riociguat.  Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13334385"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events  have not been observed in animal reproduction studies; however, increased resorption was reported in some studies. </p></div>
<div class="block brc drugH1Div" id="F20616344"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if milrinone is present in breast milk. The manufacturer recommends that caution be exercised when administering milrinone to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F196718"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">BP, heart rate, ECG, hemodynamic parameters as appropriate (eg, CVP, RAP, MAP, CI, PCWP, SVR, ScvO<sub>2</sub> or SvO<sub>2</sub>); intravascular volume status; kidney function; urine output; electrolytes (especially potassium and magnesium); platelet count.</p>
<p style="text-indent:-2em;margin-left:2em;">Consult individual institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F196709"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A selective phosphodiesterase inhibitor in cardiac and vascular tissue, resulting in vasodilation and inotropic effects with little chronotropic activity. </p></div>
<div class="block phk drugH1Div" id="F196725"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: 5 to 15 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonate (primary pulmonary hypertension of the newborn): V<sub>d</sub>: 0.56 ± 0.19 L/kg (McNamara 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants (after cardiac surgery): Vβ: 0.9 ± 0.4 L/kg (Ramamoorthy 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Children (after cardiac surgery): Vβ: 0.7 ± 0.2 L/kg (Ramamoorthy 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">After cardiac surgery: 0.31 L/kg (Das 1994).</p>
<p style="text-indent:-2em;margin-left:6em;">Heart failure (with single injection): 0.38 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Heart failure (with infusion): 0.45 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: ~70%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (minor); majority is not metabolized (Rocci 1987).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates: 10.3 hours (Paradisis 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants (after cardiac surgery): 3.15 ± 2 hours (Ramamoorthy 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Children (after cardiac surgery): 1.86 ± 2 hours (Ramamoorthy 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">Heart failure: 2.3 to 2.4 hours; kidney impairment prolongs half-life (Rocci 1987).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe heart failure undergoing continuous venovenous hemofiltration (CVVH): 20.1 ± 3.3 hours (Taniguchi 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (83% as unchanged drug; 12% as 0-glucuronide metabolite); active tubular secretion is a major elimination pathway for milrinone (Rocci 1987).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants (after cardiac surgery): 3.8 ± 1 mL/kg/minute (Ramamoorthy 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Children (after cardiac surgery): 5.9 ± 2 mL/kg/minute (Ramamoorthy 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Children (with septic shock): 10.6 ± 5.3 mL/kg/minute (Lindsay 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">After cardiac surgery: 2 ± 0.7 mL/kg/minute (Ramamoorthy 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Heart failure: 2.2 to 2.3 mL/kg/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F196728"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Milrinone | Primacor</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Corotrope | Fada milrinona | Milricor | Milrinona richet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Asicor | Corotrop | Milrinon carino | Milrinon hikma | Milrinon medicamentum</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Milrinone claris | Milrinone horizon</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Milrinon Labatec</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Corotrope</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Milrinone lactate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Coniferin | Corotrope | Milrinona | Milrox | Myomil c</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Asicord | Corotrop</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Milrinon carino | Milrinon carinopharm | Milrinon rotexmedica | Milrinon stragen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Milrinona</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Corotrope | Milricor</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Corotrope</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Milnocor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Corotrope | Milrinone carinopharm | Milrinone Medac | Milrinone panpharma | Milrinone stragen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Milrinone | Primacor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Corotrope | Unacor</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Coritrope | Inovad</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Milrinone | Primacor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Milicor | Milrineon | Milron | Milvas | Primacor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Primalon</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Milrila | Milrinone Sandoz</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Corotrope | Kardiyomil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Corotrope</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fibralina | Mirdioxane | Nuzetron | Primacor | Vilmir</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Corotrope | Milrinon Devrimed | Milrinon hikma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Milnocor | Milrinon abcur | Milrinone</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Milrinone | Primacor</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Milron</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Asicor | Corotrope</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Corotrope</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Milricor | Milrinona richet | Milrinone prosalud</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Corotrop | Milrinon abcur</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Corotrope</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Asicor | Corotrop</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Corotrope</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Kardiyomil | Milricor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Milron</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Corotrope | Milricor</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Primacor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9466032">
<a name="9466032"></a>Alhashemi JA, Hooper J. Treatment of milrinone-associated tachycardia with beta-blockers. <i>Can J Anaesth</i>. 1998;45(1):67-70. doi:10.1007/BF03011997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9466032/pubmed" id="9466032" target="_blank">9466032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated August 2022. Accessed August 15, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12595851">
<a name="12595851"></a>Aranda JM Jr, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. <i>Am Heart J</i>. 2003;145(2):324-329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/12595851/pubmed" id="12595851" target="_blank">12595851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007: 45, 145.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15346851">
<a name="15346851"></a>Bailey JM, Hoffman TM, Wessel DL, et al. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. <i>J Pharmacokinet Pharmacodyn</i>. 2004;31(1):43-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/15346851/pubmed" id="15346851" target="_blank">15346851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8625683">
<a name="8625683"></a>Barton P, Garcia J, Kouatli A, et al. Hemodynamic Effects of I.V. Milrinone Lactate in Pediatric Patients With Septic Shock. A Prospective Double-Blinded, Randomized, Placebo-Controlled, Interventional Study. <i>Chest</i>. 1996;109(5):1302-1312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/8625683/pubmed" id="8625683" target="_blank">8625683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11174341">
<a name="11174341"></a>Baruch L, Patacsil P, Hameed A, et al. Pharmacodynamic Effects of Milrinone With and Without a Bolus Loading Infusion. <i>Am Heart J</i>. 2001;141(2):266-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/11174341/pubmed" id="11174341" target="_blank">11174341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17117058">
<a name="17117058"></a>Bhat G. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy. <i>ASAIO J</i>. 2006;52(6):677-681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/17117058/pubmed" id="17117058" target="_blank">17117058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33850285">
<a name="33850285"></a>Bischoff AR, Habib S, McNamara PJ, Giesinger RE. Hemodynamic response to milrinone for refractory hypoxemia during therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy. <i>J Perinatol</i>. 2021;41(9):2345-2354. doi:10.1038/s41372-021-01049-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/33850285/pubmed" id="33850285" target="_blank">33850285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15454175">
<a name="15454175"></a>Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. <i>J Heart Lung Transplant</i>. 2004;23(9):1082-1086.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/15454175/pubmed" id="15454175" target="_blank">15454175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7587268">
<a name="7587268"></a>Chang AC, Atz AM, Wernovsky G, et al. Milrinone: Systemic and Pulmonary Hemodynamic Effects in Neonates After Cardiac Surgery. <i>Crit Care Med</i>. 1995;23(11):1907-1914.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/7587268/pubmed" id="7587268" target="_blank">7587268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620310">
<a name="23620310"></a>Charisopoulou D, Leaver N, Banner NR. Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. <i>Angiology</i>. 2014;65(4):343-349. doi:10.1177/0003319713485808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/23620310/pubmed" id="23620310" target="_blank">23620310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29045285">
<a name="29045285"></a>Chong LYZ, Satya K, Kim B, Berkowitz R. Milrinone dosing and a culture of caution in clinical practice. <i>Cardiol Rev</i>. 2018;26(1):35-42. doi:10.1097/CRD.0000000000000165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/29045285/pubmed" id="29045285" target="_blank">29045285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20643330">
<a name="20643330"></a>Costanzo MR, Dipchand A, Starling R, et al. International Society of Heart and Lung Transplantation (ISHLT) Guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2010;29(8):914-956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/20643330/pubmed" id="20643330" target="_blank">20643330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23695773">
<a name="23695773"></a>Cox ZL, Calcutt MW, Morrison TB, Akers WS, Davis MB, Lenihan DJ. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. <i>J Cardiovasc Pharmacol Ther</i>. 2013;18(5):433-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/23695773/pubmed" id="23695773" target="_blank">23695773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11911756">
<a name="11911756"></a>Cuffe MS, Califf RM, Adams KF Jr, et al. Short-Term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure: A Randomized Controlled Trial. <i>JAMA</i>. 2002;287(12):1541-1547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/11911756/pubmed" id="11911756" target="_blank">11911756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9817482">
<a name="9817482"></a>Cusick DA, Pfeifer PB, Quigg RJ. Effects of Intravenous Milrinone Followed by Titration of High-Dose Vasodilator Therapy on Clinical Outcome and Rehospitalization Rates in Patients With Severe Heart Failure. <i>Am J Cardiol</i>. 1998;82(9):1060-1065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9817482/pubmed" id="9817482" target="_blank">9817482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8155445">
<a name="8155445"></a>Das PA, Skoyles JR, Sherry KM, Peacock JE, Fox PA, Woolfrey SG. Disposition of milrinone in patients after cardiac surgery. <i>Br J Anaesth</i>. 1994;72(4):426-429. doi:10.1093/bja/72.4.426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/8155445/pubmed" id="8155445" target="_blank">8155445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28509730">
<a name="28509730"></a>Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/28509730/pubmed" id="28509730" target="_blank">28509730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31010560">
<a name="31010560"></a>Dempsey E, Rabe H. The use of cardiotonic drugs in neonates. <i>Clin Perinatol</i>. 2019;46(2):273-290. doi:10.1016/j.clp.2019.02.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/31010560/pubmed" id="31010560" target="_blank">31010560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32856285">
<a name="32856285"></a>El-Ghandour M, Hammad B, Ghanem M, Antonios MAM. Efficacy of milrinone plus sildenafil in the treatment of neonates with persistent pulmonary hypertension in resource-limited settings: results of a randomized, double-blind trial. <i>Paediatr Drugs</i>. 2020;22(6):685-693. doi:10.1007/s40272-020-00412-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/32856285/pubmed" id="32856285" target="_blank">32856285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33622380">
<a name="33622380"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. <i>Crit Care</i>. 2021;25(1):77. doi:10.1186/s13054-021-03495-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/33622380/pubmed" id="33622380" target="_blank">33622380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12651048">
<a name="12651048"></a>Felker GM, Benza RL, Chandler AB, et al. Heart Failure Etiology and Response to Milrinone in Decompensated Heart Failure: Results From the OPTIME-CHF Study. <i>J Am Coll Cardiol</i>. 2003;41(6):997-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/12651048/pubmed" id="12651048" target="_blank">12651048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23435950">
<a name="23435950"></a>Garcia Guerra G, Joffe AR, Senthilselvan A, Kutsogiannis DJ, Parshuram CS. Incidence of milrinone blood levels outside the therapeutic range and their relevance in children after cardiac surgery for congenital heart disease. <i>Intensive Care Med</i>. 2013;39(5):951-957.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/23435950/pubmed" id="23435950" target="_blank">23435950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25860636">
<a name="25860636"></a>Gist KM, Mizuno T, Goldstein SL, Vinks A. Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury. <i>Ther Drug Monit</i>. 2015;37(6):792-796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/25860636/pubmed" id="25860636" target="_blank">25860636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30664589">
<a name="30664589"></a>Hallik M, Ilmoja ML, Tasa T, et al. Population pharmacokinetics and dosing of milrinone after patent ductus arteriosus ligation in preterm infants. <i>Pediatr Crit Care Med</i>. 2019;20(7):621-629. doi:10.1097/PCC.0000000000001879<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/30664589/pubmed" id="30664589" target="_blank">30664589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18477069">
<a name="18477069"></a>Hasei M, Uchiyama A, Nishimura M, Mashimo T, Fujino Y. Correlation between plasma milrinone concentration and renal function in patients with cardiac disease. <i>Acta Anaesthesiol Scand</i>. 2008;52(7):991-996. doi:10.1111/j.1399-6576.2008.01671.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/18477069/pubmed" id="18477069" target="_blank">18477069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10426834">
<a name="10426834"></a>Hatzizacharias A, Makris T, Krespi P, et al. Intermittent Milrinone Effect on Long-Term Hemodynamic Profile in Patients With Severe Congestive Heart Failure. <i>Am Heart J</i>. 1999;138(2, pt 1):241-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/10426834/pubmed" id="10426834" target="_blank">10426834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16500560">
<a name="16500560"></a>Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. <i>J Card Fail</i>. 2006;12(1):e1-e122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/16500560/pubmed" id="16500560" target="_blank">16500560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12600913">
<a name="12600913"></a>Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children After Corrective Surgery for Congenital Heart Disease. <i>Circulation</i>. 2003;107(7):996-1002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/12600913/pubmed" id="12600913" target="_blank">12600913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773907">
<a name="11773907"></a>Hoffman TM, Wernovsky G, Atz AM, et al. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics (PRIMACORP) Study. <i>Am Heart J</i>. 2002;143(1):15-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/11773907/pubmed" id="11773907" target="_blank">11773907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31317556">
<a name="31317556"></a>Hornik CP, Yogev R, Mourani PM, et al. Population pharmacokinetics of milrinone in infants, children, and adolescents. <i>J Clin Pharmacol</i>. 2019;59(12):1606-1619. doi:10.1002/jcph.1499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/31317556/pubmed" id="31317556" target="_blank">31317556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35881893">
<a name="35881893"></a>Imam SS, El-Farrash RA, Taha AS, Saleh GA. Milrinone versus sildenafil in treatment of neonatal persistent pulmonary hypertension: a randomized control trial. <i>J Cardiovasc Pharmacol</i>. 2022;80(5):746-752. doi:10.1097/FJC.0000000000001332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/35881893/pubmed" id="35881893" target="_blank">35881893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25429380">
<a name="25429380"></a>James AT, Bee C, Corcoran JD, McNamara PJ, Franklin O, El-Khuffash AF. Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series. <i>J Perinatol</i>. 2015;35(4):268-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/25429380/pubmed" id="25429380" target="_blank">25429380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29707527">
<a name="29707527"></a>Joynt C, Cheung PY. Treating hypotension in preterm neonates with vasoactive medications. <i>Front Pediatr</i>. 2018;6:86. doi:10.3389/fped.2018.00086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/29707527/pubmed" id="29707527" target="_blank">29707527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834678">
<a name="22834678"></a>Kaakeh Y, Overholser BR, Lopshire JC, Tisdale JE. Drug-induced atrial fibrillation. <i>Drugs</i>. 2012;72(12):1617-1630. doi:10.2165/11633140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/22834678/pubmed" id="22834678" target="_blank">22834678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kleinman.1">
<a name="Kleinman.1"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(suppl 3):S876-S908.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9872607">
<a name="9872607"></a>Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. <i>Prog Cardiovasc Dis</i>. 1998;41(3):207-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9872607/pubmed" id="9872607" target="_blank">9872607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9506650">
<a name="9506650"></a>Lindsay CA, Barton P, Lawless S, et al. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. <i>J Pediatr</i>. 1998;132(2)329-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9506650/pubmed" id="9506650" target="_blank">9506650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21976129">
<a name="21976129"></a>Majure DT, Teerlink JR. Update on the management of acute decompensated heart failure [published online October 6, 2011]. <i>Curr Treat Options Cardiovasc Med</i>. doi: 10.1007/s11936-011-0149-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/21976129/pubmed" id="21976129" target="_blank">21976129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16769471">
<a name="16769471"></a>McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. <i>J Crit Care</i>. 2006;21(2):217-222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/16769471/pubmed" id="16769471" target="_blank">16769471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23132395">
<a name="23132395"></a>McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. <i>Pediatr Crit Care Med</i>. 2013;14(1):74-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/23132395/pubmed" id="23132395" target="_blank">23132395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mille.1">
<a name="Mille.1"></a>Mille FK, Ravishankar C. Cardiac disorders. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th edition. Lippincott Williams &amp; Wilkins; 2022: chap. 41.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-West-Ward.1">
<a name="West-Ward.1"></a>Milrinone Lactate in Dextrose Injection (milrinone lactate in dextrose) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; March 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Milrinone lactate injection (milrinone) [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GlandPharma.1">
<a name="GlandPharma.1"></a>Milrinone premix (milrinone) [prescribing information]. Hyderabad, India: Gland Pharma Limited; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.2">
<a name="Hikma.2"></a>Milrinone SDV (milrinone lactate) injection, USP [prescribing information]. Hollywood, FL: Somerset Therapeutics LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30607889">
<a name="30607889"></a>Mizuno T, Gist KM, Gao Z, et al. Developmental pharmacokinetics and age-appropriate dosing design of milrinone in neonates and infants with acute kidney injury following cardiac surgery. <i>Clin Pharmacokinet</i>. 2019;58(6):793-803. doi:10.1007/s40262-018-0729-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/30607889/pubmed" id="30607889" target="_blank">30607889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10226902">
<a name="10226902"></a>Pamboukian SV, Carere RG, Webb JG, et al. The Use of Milrinone in Pretransplant Assessment of Patients With Congestive Heart Failure and Pulmonary Hypertension. <i>J Heart Lung Transplant</i>. 1999;18(4):367-371.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/10226902/pubmed" id="10226902" target="_blank">10226902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18822428">
<a name="18822428"></a>Paradisis M, Evans N, Kluckow M, Osborn D. Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants. <i>J Pediatr</i>. 2009;154(2):189-195. doi:10.1016/j.jpeds.2008.07.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/18822428/pubmed" id="18822428" target="_blank">18822428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16615956">
<a name="16615956"></a>Paradisis M, Evans N, Kluckow M, Osborn D, McLachlan AJ. Pilot study of milrinone for low systemic blood flow in very preterm infants. <i>J Pediatr</i>. 2006;148(3):306-313. doi:10.1016/j.jpeds.2005.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/16615956/pubmed" id="16615956" target="_blank">16615956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16690639">
<a name="16690639"></a>Paradisis M, Jiang X, McLachlan AJ, Evans N, Kluckow M, Osborn D. Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2007;92(3):F204-F209. doi:10.1136/adc.2005.092817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/16690639/pubmed" id="16690639" target="_blank">16690639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peberdy.1">
<a name="Peberdy.1"></a>Peberdy MA, Callaway CW, Neumar, RW, et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(suppl 3):S768-S786.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS. Standardizing I.V. Infusion Concentrations: National Survey Results. <i>Am J Health Syst Pharm</i>. 2011;68(22):2176-2182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9459233">
<a name="9459233"></a>Ramamoorthy C, Anderson GD, Williams GD, Lynn AM. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. <i>Anesth Analg</i>. 1998;86(2):283-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9459233/pubmed" id="9459233" target="_blank">9459233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3304772">
<a name="3304772"></a>Rocci ML Jr, Wilson H. The pharmacokinetics and pharmacodynamics of newer inotropic agents. <i>Clin Pharmacokinet</i>. 1987;13(2):91-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/3304772/pubmed" id="3304772" target="_blank">3304772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rodgers.2016">
<a name="Rodgers.2016"></a>Rodgers JE, Reed BN. Acute decompensated heart failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L, eds. <i>Pharmacotherapy: A Pathophysiologic Approach.</i> 10th ed. McGraw-Hill; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sinclair-Pingel.1">
<a name="Sinclair-Pingel.1"></a>Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Oder Entry System [published correction appears in <i>Hosp Pharm</i>. 2007;42:84-85]. <i>Hosp Pharm</i>. 2006;41(11):1102-1106.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9854124">
<a name="9854124"></a>Stevenson LW. Inotropic Therapy for Heart Failure. <i>N Engl J Med</i>. 1998;339(25):1848-1850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9854124/pubmed" id="9854124" target="_blank">9854124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11030165">
<a name="11030165"></a>Taniguchi T, Shibata K, Saito S, et al. Pharmacokinetics of Milrinone in Patients With Congestive Heart Failure During Continuous Venovenous Hemofiltration. <i>Intensive Care Med</i>. 2000;26(8):1089-1093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/11030165/pubmed" id="11030165" target="_blank">11030165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15063407">
<a name="15063407"></a>Upadya S, Lee FA, Saldarriaga C, et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. <i>J Heart Lung Transplant</i>. 2004;23(4):466-472.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/15063407/pubmed" id="15063407" target="_blank">15063407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923988">
<a name="28923988"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/28923988/pubmed" id="28923988" target="_blank">28923988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23839530">
<a name="23839530"></a>Vogt W. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model. <i>Clin Pharmacokinet</i>. 2014;53(1):51-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/23839530/pubmed" id="23839530" target="_blank">23839530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3766576">
<a name="3766576"></a>Wilson TD, Forde MD, Crain AVR, Dombrowski LJ, Joyce MA. Stability of milrinone in 0.45% sodium chloride, 0.9% sodium chloride, or 5% dextrose injections. <i>Am J Hosp Pharm</i>. 1986;43(9):2218-2220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/3766576/pubmed" id="3766576" target="_blank">3766576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AHA.1">
<a name="AHA.1"></a>2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S640-S933.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9652 Version 307.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
